Introduction/Aim: LR769 is a new second-generation recombinant human Factor VIIa (rhFVIIa) developed for haemophilia treatment. We determined enzymatic properties of LR769 and its interaction with antithrombin, tissue factor, platelets and endothelial protein C receptor (EPCR), compared with NovoSevenRT. Methods: Kinetic enzyme assays and active site titration were used for enzymatic studies. Surface Plasmon Resonance (SPR) was used for determination of binding constants. Cellular binding was determined for platelets and cultured human umbilical vein endothelial cells (HUVEC). Results: The dissociation constant (K d ) for activated platelet binding was in the 1 lM range for both products. At saturation, more LR769 than NovoSevenRT was bound to the platelets. Binding to HUVEC was 25-50% higher for LR769 than for NovoSevenRT. Protein C, soluble EPCR, and anti-EPCR antibody all reduced the binding, indicating specificity for EPCR. . The K d values for binding of LR769 to soluble tissue factor and full-length tissue factor were 8.1 nM and 0.9 nM, respectively, and the K d for binding to soluble EPCR was 41 nM. Conclusion: Overall, LR769 exhibited characteristics similar to NovoSevenRT, but bound EPCR on HUVEC with somewhat higher affinity than NovoSevenRT.
Introduction
For the majority of haemophilia patients with inhibitors to factors VIII or IX, a bypass agent such as recombinant human Factor VIIa (rhFVIIa) must be used to facilitate clotting during bleeding episodes. The cost of this alternative treatment is three to four times higher than normal replacement therapy [1] . The major rhFVIIa product currently on the market is NovoSevenRT (eptacog alfa, Novo Nordisk Inc.), which is produced in baby hamster kidney cells. LR769 (eptacog beta) is a new recombinant human FVIIa product produced by LFB USA using rPro â Technology, a patented transgenic expression platform [2, 3] . The goal is to provide an alternative bypass agent.
A therapeutic dose of rhFVIIa leads to FVII/FVIIa plasma levels that are well above the expected concentration of tissue factor (TF), the physiological cofactor that stimulates FVIIa enzymatic activity [4] . Recent data indicate that the TF-independent mechanism, which is dependent on platelet binding, is responsible for the haemostatic effect of excess rhFVIIa in haemophilia [5] [6] [7] [8] .
In mice, binding of rhFVIIa to EPCR is involved in the uptake of rhFVIIa into tissue and has a direct effect on reducing vascular permeability [9, 10] . In vitro, human FVIIa is taken up and recycled to the cell exterior through an EPCR-dependent mechanism [11] . Human FVII/FVIIa binds to human or mouse EPCR with about the same affinity as Protein C/Activated Protein C (PC/APC) (K d = 30-150 nM) and competes for the same binding site [12] [13] [14] [15] . In a patient given a standard rhFVIIa dose, the peak plasma concentration is about equivalent to that of PC, so it is conceivable that FVIIa may bind to EPCR in patients receiving FVIIa therapy. Mouse studies suggested that increased binding to EPCR leads to better pharmacodynamics of rhFVIIa [16] .
In this report, we demonstrate that LR769 produced by LFB USA binds to human umbilical vein endothelial cells (HUVEC) at therapeutic concentrations and this binding is dependent on EPCR as measured by three independent methods. Furthermore, we demonstrate that LR769 is similar to NovoSevenRT with respect to kinetic enzyme activity, TF binding and inactivation by AT.
Materials and methods

Sources of materials
Human FX, FXa, FIX, FIXa, AT, PC and AHVII-5031 anti-FVIIa monoclonal antibody (Mab) were from Haemotologic Technologies, Essex Junction, VT, USA. For western blots and plate-binding assays, rabbit antiFVIIa polyclonal antibodies (Abcam Cambridge, MA, USA AB7053) and anti-rabbit IRDye 800 (Li-Cor, Lincoln, NE, USA) were used. Rat anti-human EPCR RCR-252, methylumbelliferyl p 0 -guanidinobenzoate (MUGB), 4-methylumbelliferone, heparin, phenylmethanesulfonyl fluoride (PMSF, 93482) and protease inhibitor cocktail (P-2714) were from Sigma, St. Louis, MO, USA. Blocking and antibody dilution was done with Odyssey Blocking Buffer PBS (Li-Cor). Soluble EPCR (sEPCR) was provided by C. Esmon [17] . Recombiplastin 2G was from Instrumentation Laboratory Bedford, MA, USA, CS-51(09) FIX substrate was from Hyphen BioMed, (Neuville-sur-Oise, France), and S2765 FX substrate was from Diapharma, Detroit, MI, USA. Chromozym t-PA FVIIa substrate was from Sigma-Aldrich, St. Louis, MO, USA. Alexafluor488-Anti-mouse IgG (A11059), A488 TFP and cell extraction buffer (FNN0011) were from Invitrogen, Carlsbad, CA, USA. Anti-mouse IgG-biotin (31813) and strep HRP (21130) were from Pierce, Rockford, IL, USA, and anti-CD41a-Percp-Cy5.5 was from Becton Dickenson, San Jose, CA, USA. HUVEC from pooled human donors were from Lonza, Portsmouth, NH, USA (C2519A). Asserachrom FVIIa ELISA was from Diagnostica Stago, Parsippany, NJ, USA (00241). Perkin Elmer Plate wash was used for westerns and plate-binding assay. NovoSevenRT (Novo Nordisk, Inc., Denmark) was obtained commercially and was reconstituted as per manufacturer's instructions before the expiration date. The concentration was determined by absorbance of 280 nM wavelength light (A 280 ) against NovoSevenRT formulation buffer. Full-length TF (TF ) was from Sekisui Diagnostics, Lexington, MA, USA. sTF 2-219, lacking the cytoplasmic and transmembrane domains and linker was produced in E. coli and provided by J. Morrissey.
LR769 purification
LR769 was purified to homogeneity from transgenic rabbit milk using a four-step downstream process including affinity and ion exchange chromatography.
FVIIa clotting assay
LR769 and NovoSevenRT were diluted to equal protein concentrations, based on total protein determination by A 280 , and assayed in triplicate with a StaClot VIIa-rTF Kit (Diagnostica Stago). Data were pooled and analysed by GraphPad Prism 5.
FX activation
Reaction mixtures containing 0.27 lL Recombiplastin 2G lL
À1
, 0.2 nM FVIIa and various FX concentrations in 25 mM HEPES, 100 mM NaCl, 5 mM CaCl 2 and 0.1% BSA, pH 7.4 were incubated for 1 to 4 min. at 37°C Reactions were quenched with EGTA, and FXa activity was determined with S2765 substrate. FXa nmole min À1 was determined using purified FXa.
FIX activation
Reaction mixtures containing 0.2 lL Recombiplastin 2G lL
À1
, 0.4 nM FVIIa and various FIX concentrations in a buffer containing 20 mM HEPES, 150 mM NaCl, 0.1% BSA, 0.1% polyethylene glycol and 5 mM CaCl 2 , pH 7.4, were incubated for 1 to 5 min at 37°C. Reactions were quenched with EDTA and FIXa activity was measured with CS-51(09) substrate. FIXa nmole min À1 was determined using purified FIXa.
Active site titration
Titration of FVIIa active sites was performed as described [18] . Samples containing 0.5 lM FVIIa, 1 lM sTF and 8.6 mM MUGB were incubated for at 37°C in a buffer containing 50 mM HEPES, 100 mM NaCl, 5 mM CaCl 2 and 0.1% BSA, pH 7.4, and fluorescence was measured over time. Calibration was accomplished with 4-methylumbelliferone.
Inactivation by AT
Samples containing 15 U mL À1 unfractionated heparin, 40 nM FVIIa, 400 nM sTF and various concentrations of AT were incubated for various times at 37°C in a reaction mixture containing 20 mM HEPES, 150 mM NaCl, 5 mM CaCl 2 and 0.1% BSA, pH 7.4. Aliquots of the reaction mix were removed at each time point and FVIIa activity was determined by adding 1 mM Chromozym tPA and measuring the change in A 405 .
Platelet isolation
Twelve millilitres of fresh blood from each donor was collected in 3.2% citrate. Platelets were isolated as described [6, 19] , stored at 37°C and used within 1 h. Platelet counts were performed with a haemocytometer.
Platelet-binding assays
Studies were performed by a modification of a published method [20] . Purified platelets were activated for 15 min at 37°C with 100 ng mL À1 convulxin and 2 nM human thrombin. FVIIa was buffer-exchanged into HEPES Tyrode's buffer containing 0.1% BSA, added to 0.5 9 10 8 mL À1 platelets and incubated at 23°C for 30 min followed by a gradual increase to 37°C and subsequent incubation at 37°C for 30 min. Platelets were washed and fixed in 1% formaldehyde and incubated with anti-FVIIa-A488 Mab and anti-CD41a-PercpCy5.5 for 1 h at room temperature with periodic mixing. Platelet activation was monitored in duplicate samples with anti-CD62-FITC. Platelets were identified by flow cytometric analysis by their characteristic log forward and side light scatter profiles and CD41-Percp-Cy5.5 positivity; FVIIa A488 Mab fluorescence signal was measured. K d and B max values were calculated by plotting the data in Excel and fitting with 4-paramater model.
Soluble EPCR binding (sEPCR)
Surface Plasmon Resonance experiments were conducted in a Biacore T200 instrument from GE Healthcare (Uppsala, Sweden). sEPCR was immobilized on a CM5 sensor chip using the standard amine coupling procedure at1 40 RU. The running buffer for the kinetic analysis was 10 mM HEPES, 150 mM NaCl, 5 mM CaCl 2 and 1 mM MgCl 2 , 0.005% Surfactant P20, pH7.5. FVIIa analytes were diluted in running buffer and injected over a concentration range of 62.5-1000 nM in one cycle. After the five concentration injections, a dissociation phase was observed during 600 s and the surface was regenerated by injecting 50 mM EDTA for 60 s. Data were analysed with Biacore Evaluation software and the K d values were obtained using the binding 1:1 kinetic model for singlecycle kinetics (SCK).
Soluble and full-length TF binding
Full-length TF (TF ) was from American Diagnostica. sTF 2-219, lacking the cytoplasmic and transmembrane domains and linker was produced in E. coli and provided by J. Morrissey. Soluble and full-length TF samples were analysed in a Biacore X100 (GE Healthcare, Uppsala, Sweden) separately by immobilization on a CM5 sensor chip using the standard amine coupling procedure at approximately 200 RU. The running buffer for the kinetic analysis was as above. FVIIa analyte was diluted in running buffer and injected during 180 s at five concentrations. After each injection of FVIIa, a dissociation phase was observed during 900 s and the surface was regenerated by injecting 50 mM EDTA for 60 s. Data were analysed with Biacore Evaluation software and the K d values were obtained using the binding 1:1 kinetic model.
Binding to HUVEC
For cell binding assays, HUVEC were cultured in 96-well plates in Endothelial Growth Medium-2 (Lonza) to >90% confluence. Cells were washed once in binding buffer (10 mM HEPES 150 mM NaCl, 4 mM KCl, 11 mM glucose, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 1% BSA, pH 7.5). FVIIa and other proteins were added in binding buffer and the plates were incubated at 2°C to 8°C for 2 to 3 h with slow mixing. Cells were washed thrice with cold binding buffer, fixed with 3.7% formaldehyde for 30 min and made permeable by washing thrice with 0.1% Triton X-100. Plates were blocked for 30 min at room temperature and primary antibody was added and incubated for 1 h at room temperature at 2°C to 8°C. Plates were washed and secondary antibody was added for 1 h at room temperature. Plates were washed and absorbance was measured with a Li-Cor Odyssey CLx.
For ELISA, 200 lL of rhFVIIa in binding buffer was added in quadruplicate to 24-well plates and incubated as above. Cells were washed thrice with cold binding buffer and extracts were prepared with cell extraction buffer containing 1 mM PMSF and protease inhibitor cocktail. A standard curve of each product was constructed by spiking purified product into extract from buffer-only wells. FVIIa in extracts was determined by ELISA. Plates were read with a Molecular Devices Spectramax M2 plate reader with Softmax version 6.4.1. For western blots, rhFVIIa preparations were bufferexchanged into the binding buffer, added to 24-well plates and incubated as above. Extracts were prepared as above and separated on SDS-PAGE gels and blotted to nitrocellulose membranes. Band intensity was measured by infrared absorption with a LiCor Odyssey CLx. Each sample was analysed on duplicate independent blots of each product.
Results
Platelet-binding studies
Analysis of FVIIa binding to platelets revealed that both LR769 and NovoSevenRT bound to activated platelets in a dose-dependent manner. As expected, binding of FVIIa required calcium and was greatly enhanced by platelet activation (Fig. 1) . Data combined from three experiments, each using platelets from a different healthy individual, yielded a K d for FVIIa of approximately 1.2 for LR769 and 0.94 lM for NovoSevenRT, suggesting that rhFVIIa binding to activated platelets occurs at low-affinity binding sites, most likely to anionic phospholipids exposed following platelet activation. Interestingly, at saturation, the B max was approximately 40% higher for LR769 than for NovoSevenRT (Fig. 1) . To determine if the differences observed between the two products were due to a difference in binding to detecting antibody, the K d for binding of the detecting antibody to each product was measured by SPR and was found to be the same (not shown).
EPCR binding
A cell-binding assay was used to compare the relative binding of LR769 and NovoSevenRT to HUVEC primary endothelial cells. Two concentrations of FVIIa were used to represent the range of plasma concentrations expected after a dose of 90 lg Kg À1 . Unexpectedly, binding was 25-40% greater for LR769 than for NovoSevenRT (Fig. 2a, c) . Binding was greater at 22 nM than at 11 nM rhFVIIa, as expected (Fig. 2c) . Binding of both products was inhibited by addition of anti-EPCR antibody but not by normal IgG control (Fig. 2b) . A 10-fold excess of PC or sEPCR reduced binding by about 50%, as reported previously [12, 13] .
Next, a more quantitative test was used to confirm HUVEC binding. After the binding reaction was performed as above, cell extracts were prepared and the FVIIa concentration in the extracts was determined by ELISA (Fig. 3 ). This study design had some important advantages: (i) standard curves were generated for each product in order to eliminate potential differences between antibody reactivity for the two products; (ii) the number of molecules bound/cell was estimated based on the average number of cells on a confluent plate, and (iii) cell fixation was not required.
The standard curves generated by spiking purified product into extract were almost identical (Fig. 3a) . At the three concentrations tested, LR769 binding was about 40% higher than NovoSevenRT. The number of molecules bound per cell was in the range expected based on published studies [12] .
We also measured FVIIa binding to HUVEC using a western blot assay (Fig. 4) . With this method, the signal was derived from an antibody-reactive band of the same size as intact FVIIa, confirming the identity of the reactive band. As with the ELISA, standard curves were generated for each product in order to eliminate potential differences between antibody reactivity.
By the western blot method, the number of molecules bound per cell was similar to that determined with the ELISA, and binding to HUVEC was 30 -50% higher for LR769 than for NovoSevenRT (Fig. 4d) . As observed with the cell-binding assay, PC and sEPCR reduced rFVIIa binding. sTF did not compete, but instead enhanced binding approximately twofold as reported previously [13, 21] . In most of the experiments shown here, frozen aliquots of rhFVIIa were used. Freezing had no effect on the results of HUVEC binding (data not shown).
Measurement of LR769 enzymatic activity and kinetic constants
LR769 exhibited essentially the same clotting activity as that of NovoSevenRT when assayed at four dilutions with the StaClot VIIa rTF kit (Fig. 5a) . Determination of kinetic constants for activation of substrates FX and FIX revealed that LR769 activated FX and FIX with a similar efficiency as that of NovoSevenRT (Fig. 5b, c , Table 1 ). The minor differences between the K m and k cat values are negligible. Active site titration of LR769 revealed that both NovoSevenRT and LR769 contained 0.7 mole of active site per mole of protein (Fig. 5d) .
TF binding
Surface Plasmon Resonance-binding studies revealed that LR769 bound to soluble TF with an affinity similar to that of NovoSevenRT (Table 2 , Fig. 6 ). FVIIabinding affinity for full-length TF in the absence of phospholipids was approximately 10-fold higher than for sTF (K d = 0.9 nM for LR769 and 0.8 nM for NovoSevenRT).
sEPCR binding
Using sEPCR coated onto SPR chips, we measured K d values of 40.6 nM for LR769 and 36.9 for NovoSevenRT (12% CV, average of four determinations each). This finding indicated a similar binding of LR769 and NovoSevenRT to EPCR in this system and was in agreement with observed values (Fig. 7 ) [12] [13] [14] .
Inactivation by AT
Formation of complexes with plasma AT is a major clearance route of rhFVIIa [22] . We found that the apparent second-order rate constants for inactivation of LR769 and NovoSevenRT by plasma AT were 5.9 and 5.7 9 10 3 M À1 s À1 , respectively (not shown), which is similar to a previous report [23] .
Discussion
LR769 and NovoSevenRT bound relatively weakly to activated platelets (K d % 1 lM) (Fig. 1) . The relatively high dissociation constant agrees with previous work by Kjalke et al. and suggests that binding involves interaction with anionic phospholipid [20, 24] . The importance of the FVIIa-EPCR interaction led us to measure binding of LR769 to sEPCR in a purified system and binding to EPCR on primary endothelial cells [10, 11, [25] [26] [27] [28] [29] [30] . Measurement of binding directly on fixed cells revealed dose-dependent rhFVIIa binding at two concentrations that are in the range of therapeutic plasma concentrations (Fig. 2a, c) . In these experiments, LR769 binding was about 25-30% greater than NovoSevenRT. Competition experiments with anti-EPCR, PC or sEPCR indicated specificity for and NovoSevenRT. These data were used to calculate TF-binding constants (Table 2) .
(a) (b) Fig. 7 . SPR characterization of FVII binding to sEPCR revealed similar profiles for LR769 (a) and NovoSevenRT (b). Background (buffer) is shown in green. These data were used to calculate sEPCR-binding constants.
Haemophilia ( EPCR (Fig. 2d, e) . Anti-EPCR completely blocked binding of NovoSevenRT to HUVEC, whereas only 91% of LR769 binding was blocked, suggesting a minor non-EPCR-binding site for LR769 (Fig. 2d) .
In the ELISA and western blot methods, cellular proteins were extracted without fixing the cells. Both methods showed equivalent reactivity of the products in the assay format (Figs 3a and 4a) and greater binding of LR769 in the HUVEC-binding reactions (Figs 3b and 4b) . The western blot confirmed that the rhFVIIa molecules in the binding reaction were fulllength size (Fig. 4a) . Competition with a 10-fold excess of Protein C or soluble EPCR indicated specificity for EPCR (Fig. 4c) . In agreement with previously reported results, addition of sTF increased binding of FVIIa to HUVEC (Fig. 4c) [13, 21] .
We do not yet know why binding of LR769 to HUVEC was higher than NovoSevenRT, given that the K d for sEPCR determined for the two products was the same when measured by SPR (Fig. 7) . In the three HUVEC-binding methods used here, the concentrations tested were near the K d value. It is possible that there is another receptor or co-receptor on HUVEC that binds LR769 with higher affinity than NovoSevenRT. The primary sequence and the degree of gamma carboxylation of LR769 are the same as for NovoSevenRT, but there are differences in glycosylation which also might affect binding. The N-glycans of LR769 are 71% complex biantennary structures sialylated at the a2-6 position. Twelve per cent are bisialylated and 57% are monosialylated [2] . In contrast, NovoSevenRT contains approximately 50% bisialylated and 18% monosialylated biantennary Nglycans that are sialylated at the a2-3 position. Similar to human plasma FVII, 29% of N-glycans on LR769 are fucosylated whereas 100% of N-glycans on NovoSevenRT are fucosylated [2, 31, 32] .
Both rhFVIIa products are nearly identical with respect to enzymatic activity and substrate interactions (Fig. 5, Table 1 ). Integrity of LR769 was further demonstrated by active site titration using MUGB (Fig. 5d, Table 1 ). The K d for TF and sTF 219 was also similar for both products (Fig. 6, Table 2 ) [33] [34] [35] . The 10-fold lower K d for TF was consistent with the observation by Higashi et al. [36] .
In summary, we have shown that a new bypass agent, LR769, is catalytically similar to NovoSevenRT, but binds slightly better to platelets and HUVEC. The binding to HUVEC is due, in part, to interaction with EPCR.
